Enhertu plus Perjeta improved progression-free survival to 40.7 months versus 26.9 months with commonplace care in superior HER2-positive breast most cancers.
Enhertu (fam-trastuzumab deruxtecan-nxki; T-DXd) mixed with Perjeta (pertuzumab) as first-line remedy improved progression-free survival (PFS) versus commonplace take care of sufferers with HER2-positive superior or metastatic breast most cancers, in response to findings from the section 3 DESTINY-Breast09 trial (NCT04784715) offered in a press briefing on the 2025 ASCO Annual Assembly.
Knowledge confirmed a median PFS of 40.7 months with Enhertu plus Perjeta versus 26.9 months with a taxane plus trastuzumab (Herceptin) and Perjeta. Within the Enhertu and THP arms, respectively, the PFS charges had been 93% versus 87.8% at 6 months, 85.9% versus 72.4% at 12 months and 70.1% versus 52.1% at 24 months.
As of the info cutoff of February 26, 2025, information had been immature.
“The mixture of [Enhertu and Perjeta] demonstrated a statistically important and clinically significant enchancment in PFS in contrast with THP,” lead research creator Dr. Sara M. Tolaney, chief of the division of Breast Oncology at Dana-Farber Most cancers Institute, in Boston, Massachusetts, said through the press briefing. “These information counsel that the mixture of [Enhertu and Perjeta] could signify a brand new first-line commonplace of take care of sufferers with metastatic HER2-positive breast most cancers.”
Based on Tolaney, the PFS profit with the Enhertu routine prolonged throughout all subgroups, which included sufferers no matter de novo or recurrent illness, hormone receptor standing, and PIK3CA mutation standing. Moreover, the median length of response (DOR) was 39 months with the Enhertu mixture, with full responses reported in 15.1% and eight.5% of the investigational and comparator arm, respectively. Tolaney additionally famous that early general survival (OS) information highlighted a pattern in direction of improved outcomes with Enhertu plus Perjeta.
The protection profile of Enhertu plus Perjeta within the DESTINY-Breast09 trial was akin to prior experiences of every particular person agent. Any-grade treatment-emergent hostile results (TEAEs) within the Enhertu and THP arms, respectively, included nausea (71.1% versus 28.8%), diarrhea (55.9% versus 54.2%), neutropenia (48.8% versus 44.5%) and fatigue (48.3% versus 34.6%). Moreover, the commonest grade 3 (extreme) or larger TEAEs in every arm included neutropenia (23.9% versus 33.2%), hypokalemia (10.2% versus 1.6%) and anemia (8.4% versus 3.7%).
Within the multicenter, open-label DESTINY-Breast09 research, sufferers with HER2-positive metastatic or superior breast most cancers had been randomly assigned 1:1:1 to obtain Enhertu at 5.4 milligram per kilogram (mg/kg) each three weeks plus placebo (387 sufferers), Enhertu plus Perjeta (383 sufferers), or a taxane consisting of paclitaxel or docetaxel together with trastuzumab and Perjeta (387 sufferers). Tolaney famous that outcomes within the Enhertu plus placebo arm would stay blinded till the time of the ultimate PFS evaluation.
The trial’s main finish level was PFS per blinded impartial central evaluation. A key secondary finish level was OS. Different secondary finish factors included PFS per investigator analysis, goal response charge, DOR and security and tolerability.
Sufferers 18 years and older with pathologically documented superior or metastatic HER2-positive breast most cancers, and no prior chemotherapy or HER2-targeted brokers for superior or metastatic illness, or only one prior line of endocrine remedy within the metastatic setting, had been eligible for enrollment on the trial. Different necessities for research entry included having satisfactory organ and bone marrow operate and an ECOG efficiency standing of 0 or 1. Investigators stratified sufferers by whether or not they had de novo or recurrent illness, hormone receptor — optimistic or hormone receptor — destructive illness and detected or non-detected PIK3CA mutations.
Reference:
“Trastuzumab deruxtecan plus Perjeta versus commonplace remedy for first-line HER2-positive superior breast most cancers” by Dr. Sara Tolaney, et al., Journal of Scientific Oncology.
For extra information on most cancers updates, analysis and schooling, don’t overlook to subscribe to CURE®’s newsletters right here.
